As a biotechnology entrepreneur and investment professional, Ernst specializes in oncology drug development and venture creation. Ernst has held key roles, including Entrepreneur-in-Residence at Sapreme Technologies and Chief Business Officer at Flindr Therapeutics.

Currently, he serves as CEO at Genase Therapeutics and works with other oncology biotechs, investors and venture creators as consultant or CxO/EiR. He was a partner with Aglaia Oncology Funds, a boutique venture capital firm that is specialized in early-stage oncology therapeutics investments and venture creation. Ernst developed this entrepreneurial spirit in his academic life working in the laboratory of Hidde Ploegh at Harvard Medical School and at the translational cancer research group of Prof. Rene Bernards at the Netherlands Cancer Institute.